1513MO A phase II study of nivolumab plus low dose ipilimumab as first -line therapy in patients with advanced gastric or esophago-gastric junction MSI-H tumor: First results of the NO LIMIT study (WJOG13320G/CA209-7W7)
Kei Muro, Hisato Kawakami, Shigenori Kadowaki, Akitaka Makiyama, Masahiro Tsuda, Kenro Hirata, Naotoshi Sugimoto, Nozomu Machida, Hiroki Hara, Hidekazu Hirano, Taito Esaki, Yoshito Komatsu, Shuichi Hironaka
Topics & Concepts
MedicineNivolumabIpilimumabInternal medicineClinical endpointGastroenterologyPhases of clinical researchCancerResponse Evaluation Criteria in Solid TumorsOncologyProgression-free survivalMicrosatellite instabilityProgressive diseaseSurgeryToxicityChemotherapyImmunotherapyClinical trialMicrosatelliteBiochemistryGeneAlleleChemistryGastric Cancer Management and OutcomesGastrointestinal Tumor Research and TreatmentCancer Immunotherapy and Biomarkers